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Background In randomized clinical trials, the risk of
thrombotic events with the absorb bioresorbable vascular
scaffold (BVS) was significantly higher than with metallic
drug-eluting stents. We evaluated predictors of scaffold
thrombosis in the large-scale, multicenter German–Austrian
ABSORB RegIstRy.
Methods and results 3178 patients with treatment of 4252
lesions using 5020 scaffolds were included. Follow-up rate
at 6 months was 97.4%. Forty-five (1.42%) patients
experienced definite/probable scaffold thrombosis during
follow-up. Multiple regression analysis showed implantation
of absorb BVS in bifurcation lesions [odds ratio (OR): 4.43;
95% confidence interval (CI): 1.69–11.59; P= 0.0024] or
treatment in the years 2013/2014 (OR: 1.88; 95% CI:
1.02–3.47; P= 0.04) to be significant predictors of scaffold
thrombosis. Excluding bifurcation lesions, the incidence of
definite/probable scaffold thrombosis decreased from 1.8%
(95% CI: 1.17–2.64%) in 2013/2014 to 0.89% (95% CI:
0.5–1.46%) in 2015/2016. In the latter period, absorb BVS
were implanted more often in younger patients with less
complex de novo lesions, and debulking devices and
postdilatation were used more frequently. Between the two
treatment periods, there was a significant reduction in
myocardial infarction (2.73–1.24%, P< 0.01; OR: 0.45; 95%
CI: 0.26–0.77), definite/probable scaffold thrombosis
(1.79–0.88%, P< 0.05; OR: 0.49; 95% CI: 0.26–0.93), and
target lesion failure and revascularization during follow-up.
Conclusion Improved procedural technique and more
strict patient selection may explain a significant decrease in
the absorb BVS thrombosis rates during the recruitment
period of the large-scale German–Austrian ABSORB
RegIstRy. In addition, treatment of bifurcation lesions was
identified as an independent predictor of definite/probable
scaffold thrombosis. Coron Artery Dis 29:389–396
Copyright © 2018 Wolters Kluwer Health, Inc. All rights
reserved.
Coronary Artery Disease 2018, 29:389–396
Keywords: absorb, drug-eluting stent, follow-up,
percutaneous coronary intervention, scaffold, thrombosis
aDepartment of Internal Medicine II, Cardiology, University Hospital of Ulm, Ulm,
bDepartment of Cardiology, University of Giessen, Medizinische Klinik I, Giessen,
cElisabeth-Krankenhaus, Klinik für Kardiologie und Angiologie, Essen,
dDepartment of Cardiology, Friedrich-Alexander University Erlangen-Nürnberg,
Erlangen, eIHF GmbH, Institut für Herzinfarktforschung, Ludwigshafen,
fDepartment of Cardiology, Munich University Clinic, LMU, Munich, gUniversity
Medical Center, Johannes Gutenberg University Mainz, hMedizinische Klinik und
Poliklinik, University Medical Center Mainz, Universitätsmedizin Mainz, iAbbott
Vascular Deutschland, Wetzlar, jSegeberger Kliniken GmbH, Herzzentrum, Bad
Segeberg, kHerzzentrum Ludwigshafen, Abteilung für Kardiologie, Ludwigshafen,
lBethanien Hospital, Frankfurt, mDepartment of Cardiology, Kerckhoff Heart and
Thorax Center, Bad Nauheim, Germany and nDepartment of Cardiology, University
of Vienna Medical School, Vienna, Austria
Correspondence to Jochen Wöhrle, MD, Department of Internal Medicine II,
Cardiology, University Hospital of Ulm, 89081 Ulm, Germany
Tel: + 49 731 5004 5047; fax: + 49 731 5004 5029;
e-mail: jochen.woehrle@uniklinik-ulm.de
Received 12 January 2018 Revised 2 March 2018 Accepted 4 March 2018
Introduction
Randomized clinical trials and meta-analyses showed a
higher risk of thrombotic events with use of the absorb
bioresorbable vascular scaffold (BVS) compared with
metallic drug-eluting stents (DESs) for the treatment of
de novo coronary artery disease [1–3]. In addition, early
real-world registries also showed a high risk of thrombotic
events [4]. After the initial learning curve with the absorb
scaffold, the present state-of-the-art implantation strategy
includes careful patient selection, predilatation, proper
sizing, and postdilatation to improve outcome with the
absorb BVS [5].
We sought to determine predictors of scaffold thrombosis and
the impact of the learning curve in the large-scale, multi-
center, German–Austrian ABSORB RegIstRy (GABI-R).
Methods
Between November 2013 and January 2016, 3264
patients underwent percutaneous coronary intervention
(PCI) using the absorb BVS (Abbott Vascular, Santa
Clara, California, USA) in 93 GABI-R centers in
Germany and Austria. A detailed description of GABI-R
has been published previously [6]. In brief, GABI-R is an
international, multicenter, large-scale observational registry.
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The decision to perform PCI using an absorb BVS was at
the operator’s discretion. Patient treatment was based on
local standards. The study was carried out in accordance
with the Declaration of Helsinki and the International
Conference on Harmonization Good Clinical Practice. The
ethics committees of participating centers approved the
registry protocol. All patients provided written, informed
consent.
Procedure
Lesion preparation, including predilatation, use of
debulking devices, or periprocedural use of intracoronary
imaging, was left to the operator’s discretion to reflect
real-world use of the absorb BVS. Antiplatelet therapy
consisted of aspirin (loading dose 250–500 mg and
maintenance dose 100 mg/day) and either clopidogrel
(loading dose ≥ 300 mg and maintenance dose 75mg/
day), prasugrel (loading dose 60mg and maintenance
dose 10 mg/day), or ticagrelor (loading dose 180 mg and
maintenance dose 90 mg, twice daily). Dual antiplatelet
therapy was recommended for at least 12 months.
Data management
Data were collected electronically using an internet-based
application, and centrally stored and analyzed by the Institut
für Herzinfarktforschung (IHF GmbH, Ludwigshafen,
Germany). All events were adjudicated and classified by an
independent event adjudication committee.
Scaffold thrombosis was defined as definite or probable
according to Academic Research Consortium criteria [7].
Cardiac death was defined as death from immediate
cardiac causes or complications related to the procedure
as well as any death in which a cardiac cause could not be
excluded. Myocardial infarction (MI) was defined
according to the WHO extended definition [8]. Target
lesion failure (TLF) was defined as a composite of car-
diac death, target vessel MI, and clinically driven target
lesion revascularization (TLR).
Statistical analysis
Distributions of metric variables within the two groups
(with and without scaffold thrombosis) are described by
mean ± SD. Binary variables are described by absolute
frequencies and percentages. Frequencies of outcomes
are complemented by odds ratios and 95% confidence
limits, where possible. All descriptive statistics are based
on known values. A multiple logistic regression model
was used to identify predictors of scaffold thrombosis
among baseline and procedural variables. Predictor vari-
ables in the model were initially prespecified and then
reduced after assessing the results of a preliminary
model. To reduce the number of predictors, a stepwise
algorithm was applied in which an empirical significance
level of P value up to 0.1 was required for each variable to
enter the final model. Missing values were imputed
either by modal values (if binary variables were missing)
or by median values (metrical variables). A two-tailed
P-value less than 0.05 was considered to indicate statis-
tical significance. Statistical analysis was carried out using
SAS software, version 9.3 (SAS Institute Inc., Cary, North
Carolina, USA).
Results
Patient and procedural characteristics
A total of 3264 patients who underwent PCI with absorb
BVS implantation were enrolled in the GABI-R registry.
The follow-up rate at 6 months was 97.4%, including
3178 patients with treatment of 4252 lesions using 5020
absorb BVS. Of the 3178 patients, 45 (1.42%) patients
experienced a definite or probable scaffold thrombosis
(Fig. 1). Baseline clinical parameters, including sex, car-
diovascular risk factors, route of coronary intervention,
number of diseased vessels, clinical presentation with an
acute coronary syndrome, and use of antiplatelet therapy
and oral anticoagulation, were similar in patients with and
without scaffold thrombosis (Table 1). Angiographic and
procedural characteristics of patients with and without
scaffold thrombosis are detailed in Table 2. Between
these two groups, there was no difference with respect to
lesion complexity, presence of a de novo lesion, amount
of calcification, use of predilatation or debulking devices,
implantation pressure, use of postdilatation, and final
thrombolysis in myocardial infarction (TIMI) 3 flow.
There was a significantly higher rate of treated bifurca-
tion lesions (7.5 vs. 2.9%, P< 0.05) and a significantly
higher rate of TIMI 3 flow before coronary intervention
in patients with subsequent scaffold thrombosis than in
patients without scaffold thrombosis (Table 2).
Multiple regression analysis for predictors of scaffold
thrombosis
Predictors of scaffold thrombosis are listed in Table 3.
There was a somewhat higher, but insignificant risk of
scaffold thrombosis in patients with diabetes mellitus and
in those presenting with acute coronary syndromes, for
the implantation of longer scaffolds, the lack of post-
dilatation, smaller scaffold diameters, and the use of
clopidogrel versus prasugrel/ticagrelor after the inter-
vention. The only significant predictors of scaffold
thrombosis were the implantation of a scaffold in a
bifurcation lesion [odds ratio (OR): 4.50; 95% confidence
interval (CI): 1.68–12.06; P= 0.003] and treatment within
the time period 2013/2014 versus the time period
2015/2016 (OR: 1.91; 95% CI: 1.03–3.57; P= 0.041). After
stepwise variable selection, implantation of an absorb
BVS in a bifurcation (OR: 4.43; 95% CI: 1.69–11.59;
P= 0.0024) or treatment in 2013/2014 (OR: 1.88; 95% CI:
1.02–3.47; P= 0.04) remained significant predictors of the
occurrence of scaffold thrombosis.
We analyzed the dataset for additional predictors of
scaffold thrombosis by excluding patients with scaffold
implantation in bifurcation lesions, but including the
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other variables (Table 3). The implantation of an absorb
BVS in the years 2013/2014 was the only remaining sig-
nificant predictor of scaffold thrombosis (OR: 1.98; 95%
CI: 1.03–3.82; P= 0.04).
Absorb bioresorbable vascular scaffold thrombosis
As shown in Fig. 2, the incidence of scaffold thrombosis
was 5.81% (95% CI: 1.91–13.05%) in bifurcation lesions
treated with an absorb BVS. Excluding bifurcation
lesions, the incidence of definite/probable scaffold
thrombosis decreased from 1.8% (95% CI: 1.17–2.64%) in
the treatment period 2013/2014 to 0.89% (95% CI:
0.5–1.46%) in the treatment period 2015/2016. The
cumulative incidence of definite scaffold thrombosis and
the daily occurrence of scaffold thrombosis for both
treatment periods are shown in Fig. 3. The majority of
thrombotic events occurred within the first 30 days.
Differences between the two treatment periods
In the treatment period 2015/2016 with a lower rate of
thrombotic events, patients were significantly younger
and hyperlipoproteinemia or chronic kidney disease was
significantly less frequent (Table 4). Scaffold implanta-
tion was performed more often in de novo lesions and in
less complex lesions, and debulking devices and post-
dilatation were used more frequently. After excluding
patients with scaffold implantation in bifurcation lesions,
we compared the two treatment periods for the occur-
rence of various events (Fig. 4). In 2015/2016 versus
Fig. 1
Cumulative incidence of definite/probable scaffold thrombosis within 6 months after absorb bioresorbable vascular scaffold implantation. Daily
occurrence of acute or subacute scaffold thrombosis is shown in gray and late scaffold thrombosis in black.





Number of patients 45 3123
Age (years) 64.1 ±10.5 60.8 ± 11.0 0.07
Women 26.7% (12/45) 23.1% (721/3123) 0.57
Diabetes mellitus 32.6% (14/43) 20.9% (647/3097) 0.06
History of smoking 52.4% (22/42) 58.2% (1721/2957) 0.45
Arterial hypertension 82.2% (37/45) 73.1% (2251/3079) 0.17
Hyperlipoproteinemia 55.6% (25/45) 56.4% (1685/2986) 0.91
Chronic kidney disease 11.1% (5/45) 7.9% (245/3099) 0.43




4.4% (2/45) 2.4% (75/3110) 0.38
Atrial fibrillation 11.1% (5/45) 6.8% (209/3077) 0.26
ACS at presentation 51.1% (23/45) 51.6% (1610/3122) 0.95
ACS presenting with
STEMI
17.4% (4/23) 33.8% (544/1610) 0.10
Heart rate (bpm) 76 ±15 72 ±14 0.09
Left ventricular ejection
fraction (%)
51 ±13 56 ± 10 0.11
Radial access 51.1% (23/45) 47.7% (1489/3122) 0.65
Severity of CAD
Single-vessel CAD 35.6% (16/45) 41.8% (1305/3123) 0.40
Two-vessel CAD 35.6% (16/45) 31.1% (970/3123) 0.52
Three-vessel CAD 28.9% (13/45) 27.1% (847/3123) 0.79
Periprocedural MI 4.4% (2/45) 0.2% (6/3122) <0.01
Prasugrel at
discharge
26.2% (11/42) 34.1% (1041/3049) 0.28
Ticagrelor at
discharge
16.7% (7/42) 22.0% (671/3049) 0.41
Oral anticoagulation
at discharge
13.6% (6/44) 7.9% (245/3121) 0.16
Values are mean ±SD or % (absolute number/number of available records).
ACS, acute coronary syndrome; CAD, coronary artery disease; MI, myocardial
infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myo-
cardial infarction.
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2013/2014, all-cause mortality was 1.24% (95% CI:
0.77–1.76%) versus 1.08% (95% CI: 0.60–1.77%, P= 0.68;
OR: 1.15; 95% CI: 0.59–2.24), cardiac death 0.47% (95%
CI: 0.20–0.93%) versus 0.22% (95% CI: 0.04–0.63%,
P= 0.23; OR 2.19; 95% CI: 0.58–8.29), MI 1.24% (95%
CI: 0.77–1.88%) versus 2.73% (95% CI: 1.94–3.72%;
P< 0.01; OR: 0.45; 95% CI: 0.26–0.77), definite/probable
scaffold thrombosis 0.88% (95% CI: 0.50–1.45%) versus
1.79% (95% CI: 1.16–2.64%; P< 0.05; OR: 0.49; 95% CI:
0.26–0.93), TLF 1.83% (95% CI: 1.24–2.58%) versus
3.01% (95% CI: 2.18–4.05%; P< 0.05; OR: 0.60; 95% CI:
0.37–0.96) and TLR 1.18% (95% CI: 0.72–1.81%) versus
2.51% (95% CI: 1.75–3.47%; P< 0.01; OR: 0.46; 95% CI:
0.27–0.81).
Discussion
Our data indicate that in the large-scale, international,
multicenter GABI-R registry, the risk of thrombotic
events after absorb BVS implantation decreased sig-
nificantly from the first to the second half of the 4-year
recruitment period. In addition, we found that implan-
tation of an absorb BVS in a bifurcation lesion was
associated with a significantly higher risk of subsequent
scaffold thrombosis. The reduction of thrombotic events
between the two implantation periods was probably
because of a combination of various factors such as more
careful patient selection, improved implantation tech-
nique with predilatation and postdilatation using a high-
pressure balloon, a shift to younger patients with less
complex lesions, and an increased focus on de novo
coronary artery disease.
In randomized clinical trials and meta-analyses, the risk
of thrombotic events after implantation of the absorb
BVS was shown to be higher than after implantation of
metallic DES [1,9–11]. The risk of absorb scaffold
thrombosis has been shown to be significantly higher in
lesions with smaller reference diameters and for proce-
dures without postdilatation versus those with balloon
postdilatation. However, randomized-controlled trials
included predominantly noncomplex de novo lesions. In
a real-world population, the rate of scaffold thrombosis
was 2.1% within 6 months [4]. In the recently published
Amsterdam Investigator-Initiated Absorb Strategy All-
Comers trial, 1845 patients with lesions up to 70 mm
were randomized to absorb BVS or everolimus-eluting
DES. The risk of a thrombotic event with absorb BVS
Table 2 Angiographic and procedural characteristics
With scaffold thrombosis Without scaffold thrombosis P value
Number of total lesions 67 4248
Number of implanted scaffolds 81 4319
Treated vessel
Left main coronary artery 0.0% (0/67) 0.5% (22/4248) 0.55
Left anterior descending artery 56.7% (38/67) 45.6% (1935/4248) 0.07
Left circumflex artery 20.9% (14/67) 21.5% (914/4248) 0.90
Right coronary artery 22.4% (15/67) 32.3% (1374/4248) 0.08
Venous graft 0.0% (0/67) 0.1% (3/4248) 0.83
Complex lesions (AHA/ACC type B2/C) 31.3% (21/67) 36.4% (1542/4240) 0.40
De novo lesion 94.0% (63/67) 94.2% (3997/4242) 0.95
Intravascular imaging after PCI 4.5% (3/67) 3.7% (155/4245) 0.72
Treated bifurcation lesion 7.5% (5/67) 2.9% (121/4242) <0.05
Lesion length >34mm 7.6% (5/66) 5.6% (235/4228) 0.48
Calcified lesion
None 28.4% (19/67) 36.0% (1527/4240) 0.19
Mild 50.7% (34/67) 41.8% (1774/4240) 0.14
Moderate 20.9% (14/67) 18.6% (787/4240) 0.63
Severe 0.0% (0/67) 3.6% (152/4240) 0.11
Coronary artery flow before PCI
TIMI 0 9.0% (6/67) 13.5% (571/4236) 0.28
TIMI 1 1.5% (1/67) 8.0% (337/4236) 0.05
TIMI 2 11.9% (8/67) 15.4% (654/4236) 0.43
TIMI 3 77.6% (52/67) 63.1% (2674/4236) <0.05
Predilatation 94.0% (63/67) 91.7% (3890/4244) 0.49
Debulking device use 6.3% (4/63) 8.8% (342/3890) 0.50
Implanted device size (mm) 3.0 ±0.38 (81) 3.1 ±0.6 (4920) 0.13
Mean total device length (mm) 20.5 ± 6.0 (81) 19.7 ±6.2 (4920) 0.21
Device implantation pressure (bar) 13.1 ±2.5 13.5 ±2.7 0.23
Scaffolds and DES implantation 4.5% (3/67) 2.9% (122/4248) 0.44
Postdilatation performed 67.2% (45/67) 72.5% (3073/4241) 0.34
Postdilation balloon size (mm) 3.3 ± 0.4 (45) 3.3 ±0.5 (3068) 0.57
Postdilation balloon pressure (atm) 16.4 ±4.6 16.7 ±4.1 0.46
Final TIMI flow 3 100% (67/67) 98.1% (4156/4237) 0.25
Overlapping scaffolds 13.3 (6/45) 12.6% (394/3123) 0.89
Coronary perforationa 0.0% (0/44) 0.5% (17/3120) 0.62
Values are mean ±SD or % (absolute number/number of available records).
AHA/ACC, American Heart Association/American College of Cardiology; DES, metallic drug-eluting stent; PCI, percutaneous coronary intervention; TIMI, thrombolysis in
myocardial infarction.
aThe majority of perforations occurred with the scaffold implantation.
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was significantly higher than with metallic DES within a
2-year period (3.5 vs. 0.9%, hazard ratio 3.87; 95% CI:
1.78–8.42; P< 0.0001). Within the first 12 months, the
risk of definitive thrombotic events was 4.25 times higher
(95% CI: 1.43–12.64) for absorb BVS than for metallic
DES. On comparing 31 patients with definite scaffold
thrombosis with 1106 patients without definite scaffold
thrombosis in the randomized Amsterdam Investigator-
Initiated Absorb Strategy All-Comers trial, the authors
could not identify differences between the two groups
with respect to predilatation, device diameter, device
length, or postdilatation, except for a higher rate of
postprocedural diameter stenosis in lesions with sub-
sequent thrombotic events. In the large-scale GABI-R
registry, 45 patients with scaffold thrombosis were com-
pared with 3123 patients without scaffold thrombosis. We
were able to show that use of a scaffold in a bifurcation
lesion and implantation during the first half of the study
period were significant predictors of scaffold thrombosis.
Indeed, the risk of scaffold thrombosis in bifurcation
lesions was 5.81%. In addition, the risk of scaffold
thrombosis within 6 months in lesions without bifurca-
tions halved in GABI-R from 1.8% in the treatment
period 2013/2014 to 0.89% in the treatment period
2015/2016. In addition to a more careful patient and lesion
selection in the later period (younger patients with less
complex lesion morphology), there was a significant change
in implantation technique, with a higher usage of pre-
dilatation, postdilatation, debulking devices, and high-
pressure balloons. These multiple, influencing variables
resulted in a significantly lower rate of MI, significantly
lower rates of definite or probable scaffold thrombosis, and
also significantly lower rates of TLF and TLR.
Although a higher risk of thrombotic events for absorb
BVS than for metallic DES is well documented [1,3,12,
13], the usage of predilatation or postdilatation could not
be differentiated as significant predictors of thrombotic
events in a recent meta-analysis including 10 510 patients
[14]. In contrast, small, single-center, and multicenter
registries reported low rates of thrombotic events [15],
even in complex lesions with overlapping scaffolds [16]
or chronic total occlusions [17,18].
An important issue is the use of an optimized implan-
tation strategy with BVS, which has been shown to
significantly reduce the occurrence of scaffold throm-
bosis within the first 12 months [19]. In addition, we
could show that reducing scaffold thrombosis in absorb
BVS (to rates that are probably comparable to those in
metallic DES) is a multivariable process that cannot be
attributed to a single parameter such as the use of
postdilatation or intracoronary imaging. Nevertheless,




Multivariable logistic analysis including all patients
Diabetes mellitus 1.69 0.88–3.23 0.116
Oral anticoagulants 0.73 0.17–3.17 0.678
Acute coronary syndrome 1.50 0.77–2.91 0.233
Total implanted scaffold length
(cm)
1.12 0.96–1.32 0.155
Predilatation 1.95 0.46–8.25 0.366
Postdilatation 0.79 0.41–1.51 0.472
Scaffold diameter <3.0 mm 1.26 0.66–2.39 0.487
Intravascular imaging after PCI 1.74 0.71–4.26 0.223
TIMI 0–2 vs. 3 after PCI 0.00 – 0.981










Multivariable logistic analysis excluding patients with bifurcations
Diabetes mellitus 1.36 0.67–2.76 0.393
Oral anticoagulants 0.75 0.17–3.22 0.696
Acute coronary syndrome 1.37 0.68–2.73 0.376
Total implanted scaffold length
(cm)
1.11 0.93–1.33 0.231
Predilatation 1.65 0.39–7.05 0.499
Postdilatation 0.79 0.40–1.56 0.490
Scaffold diameter <3.0 mm 1.19 0.60–2.39 0.615
Intravascular imaging 1.62 0.62–4.27 0.326
TIMI 0–2 vs. 3 after PCI 0.00 – 0.985










AHA/ACC, American Heart Association/American College of Cardiology; PCI,
percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
Fig. 2
Incidence (and 95% confidence intervals) of absorb bioresorbable
vascular scaffold thrombosis in bifurcation lesions (left), treatment
period 2013/2014 without bifurcation lesions (middle), and treatment
period 2015/2016 without bifurcation lesions (right).
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even with a similar rate of thrombotic events between
absorb BVS and metallic DES, the advantages of using
bioresorbable scaffolds over metallic stents remain to
be determined.
Limitations
Our study has several limitations. First, the follow-up is
relatively short of 6 months. However, the majority of
scaffold thrombosis occurs within this early time per-
iod. In addition, although GABI-R is a large multi-
center registry, there were only 45 cases with scaffold
thrombosis, which limits the power to analyze pre-
dictors for this relatively rare event. Predictors for
scaffold thrombosis may differ within the first 6 months
to the later period, which may be addressed in future
analysis.
Fig. 3
Occurrence of definite scaffold thrombosis within the treatment period 2013/2014 (a) and 2015/2016 (b). Acute or subacute scaffold thrombosis is
depicted in gray and late scaffold thrombosis is depicted in black. There was a lower rate of cumulative definite scaffold thrombosis in the later
treatment period. Most thrombotic events occurred within the first 30 days in both treatment periods.
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Conclusion
The risk of scaffold thrombosis with absorb BVS in the
large-scale, international, multicenter GABI-R registry
was shown to be the highest in bifurcation lesions. This
risk decreased during the treatment period because of a
more careful patient selection and implantation proce-
dure, resulting in significantly lower rates of MI, definite
or probable scaffold thrombosis, and TLR.
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